

Day: Friday Date: 6/16/2006

Time: 17:40:50


Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Sharpe	Stefan	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page



Day: Friday Date: 6/16/2006

Time: 17:40:50

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Sequeira	Joel	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Refine Search

Search Results -


Terms	Documents
L7 and @pd<20030822	34

US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database

Database:

EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:



Search History

DATE: Friday, June 16, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
•	PB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YE	ES; OP = OR	
. F8	L7 and @pd<20030822	34	L8
L7	L6 and ((HFA adj 227) or (heptafluoropropane))	136	<u>L7</u>
L6	(mometasone adj furoate)	1150	L6
DB=USF	PT; PLUR=YES; OP=OR		
L5	6365581.pn.	1	<u>L5</u>
DB=PGI	PB, USPT; PLUR=YES; OP=OR		
L4	L3 and mometasone	30	L4
L3 .	Joel near Sequeira	51	L3
L2	Stefan near Sharpe	7	L2
DB=PGI	PB; PLUR=YES; OP=OR		
L1	20050147565	1	L1

END OF SEARCH HISTORY





GULFIERI ARIGUE

A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Rec

		, ,	ww.puome	a.gov				
All Databases	PubMed	Nucleotide P	rotein Gen	ome Structu	re OMIM	PMC	Journals	B.
Search PubMed	for mometasone furoate and HFA-227				Go	Clear Sav	ve S	
	Limits	Preview/Inde	x History	Clipboard	Details	``		
	☐ 1: Clin Ther. 2000 Dec;22(12):1483-93.				Rela	ated Articles,	Links	

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAO
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.

Pickering H, Pitcairn GR, Hirst PH, Bacon PR, Newman SP, Affrime MB, Marino M.

Pharmaceutical Profiles Ltd, Nottingham, United Kingdom.

BACKGROUND: A new inhaled suspension formulation of mometasone furoate (MF), a potent corticosteroid with minimal systemic availability, has been developed for the treatment of asthma. This formulation is delivered by metered-dose inhaler (MDI) using the nonchlorofluorocarbon propellant hydrofluoroalkane 227 (HFA-227). OBJECTIVE: The primary goal of this study was to determine the respiratory tract deposition of this formulation of MF. A secondary objective was to measure plasma concentrations of MF and a putative metabolite, 6-X-OH MF, to determine the systemic exposure to corticosteroid. METHODS: This was a single-dose, open-label study in which 200 microg of technetium 99m (99mTc)-radiolabeled MF was administered to patients with asthma. Gamma scintigraphy was used to quantify lung, oropharyngeal, stomach, and MDI mouthpiece deposition patterns of MF. RESULTS: Eleven patients, aged 21 to 47 years, with a history of asthma were enrolled in and completed the study. The mean (+/-SD) whole lung deposition of MF was 13.9%+/-5.7% of the metered (exvalve) dose. The central lung zone received 5.3%+/-2.8% of the dose; the intermediate zone received 4.7%+/-1.9%; and peripheral lung deposition was 4.0%+/-1.5%. The mean (+/- SD) ratio of peripheral to central lung deposition was 0.8+/-0.2. Oropharyngeal deposition was 79.1%+/-8.7% of the ex-valve dose, with 6.3%+/-7.8% deposited on the MDI mouthpiece and 0.7%+/-0.5% exhaled. The majority of plasma samples taken for analysis of MF and 6-13-OH MF concentrations were below the limit of quantification (50 pg/mL) in all patients after inhalation of 200 microg 99mTc-labeled ME CONCLUSION: The lung deposition of MF when administered via HFA-227 MDI is comparable to the 10 to 20% lung deposition seen with other corticosteroid suspension for- mulations administered by MDI that have demonstrated effectiveness in the treatment of asthma.

Publication Types:

- Clinical Trial
- Historical Article